KGKristalyn K. Gallagher

Kristalyn K. Gallagher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristalyn K. Gallagher has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Axillary Reverse Mapping on Non-lymphedema Functional Axillary Complications After Axillary Lymph Node Dissection for Breast Cancer

    by Kristen Williams, Katherine Lecroy, Mu Jin, Abbey E. Skinner, Margaret Lillie, Chris B. Agala, David W. Ollila, Kristalyn K. Gallagher, Sasha E. Knowlton, Philip M. Spanheimer, et al.

  • Open Access

    ASO Visual Abstract: Analysis of Specimen Mammography with Artificial Intelligence to Predict Margin Status

    by Kevin A. Chen, Kathryn E. Kirchoff, Logan R. Butler, Alexa D. Holloway, Muneera R. Kapadia, Cherie M. Kuzmiak, Stephanie M. Downs-Canner, Phillip M. Spanheimer, Kristalyn K. Gallagher, Shawn M. Gomez

  • Analysis of Specimen Mammography with Artificial Intelligence to Predict Margin Status

    by Kevin A. Chen, Kathryn E. Kirchoff, Logan R. Butler, Alexa D. Holloway, Muneera R. Kapadia, Cherie M. Kuzmiak, Stephanie M. Downs-Canner, Phillip M. Spanheimer, Kristalyn K. Gallagher, Shawn M. Gomez

    Intraoperative specimen mammography is a valuable tool in breast cancer surgery, providing immediate assessment of margins for a resected tumor. However, t


  • Open Access

    Computer Vision Analysis of Specimen Mammography to Predict Margin Status

    by Kevin A Chen, Kathryn E Kirchoff, Logan R Butler, Alexa D Holloway, Muneera R Kapadia, Kristalyn K Gallagher, Shawn M Gomez

    Intra-operative specimen mammography is a valuable tool in breast cancer surgery, providing immediate assessment of margins for a resected tumor. However, the accuracy of specimen mammography in detecting microscopic margin positivity is low. We sought to develop a deep learning-based model to predict the pathologic margin status of resected breast tumors using specimen mammography. A dataset of specimen mammography images matched with pathology reports describing margin status was collected. Models pre-trained on radiologic images were developed and compared with models pre-trained on non-medical images. Model performance was assessed using sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC). The dataset included 821 images and 53% had positive margins. For three out of four model architectures tested, models pre-trained on radiologic images outperformed domain-agnostic models. The highest performing model, InceptionV3, showed a sensitivity of 84%, a specificity of 42%, and AUROC of 0.71. These results compare favorably with the published literature on surgeon and radiologist interpretation of specimen mammography. With further development, these models could assist clinicians with identifying positive margins intra-operatively and decrease the rate of positive margins and re-operation in breast-conserving surgery.

  • Open Access

    Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer

    by Selena J. An, Emilie D. Duchesneau, Paula D. Strassle, Katherine Reeder-Hayes, Kristalyn K. Gallagher, David W. Ollila, Stephanie M. Downs-Canner, Philip M. Spanheimer

    Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The role of de-escalated therapy in the neoadjuvant setting, however, remains uncertain. We conducted a cohort study of adult women with T1-2/cN0 HER2+ breast cancer diagnosed 2013–2016 in the National Cancer Database treated with neoadjuvant chemotherapy (NAC) and HER2-targeted therapy. Factors associated with pathologic complete response (pCR) and overall survival were examined. In total, 6994 patients were included, 32% cT1 and 68% cT2. Multi-agent NAC was given to 90% of women while single-agent NAC was given to 10% of women. pCR was achieved in 46% of cT2 patients and 43% of cT1, and in 46% of patients treated with multi-agent versus 38% single agent. Patients receiving multi-agent chemotherapy were younger, had fewer comorbidities, and had higher cT stage and grade. In all patients, pCR was associated with improved survival (p < 0.01). Multi-agent chemotherapy (OR 1.3, p = 0.003), hormone receptor negative (OR 2.6, p < 0.001), higher grade (OR 2.2, p < 0.001), younger age (OR 1.4, p = 0.011), and later year of diagnosis (OR 1.3, p = 0.005) were associated with achieving pCR. Multi-agent chemotherapy was associated with higher likelihood of pCR, but this effect was modest compared to other factors. Single-agent NAC with HER2-directed therapy in selected patients may provide excellent outcome with reduced toxicity, while allowing escalated therapy in the adjuvant setting for patients with residual disease. Prospective studies are needed to determine effects of de-escalation in the neoadjuvant setting on survival and optimal selection strategies.


  • Open Access

    The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment

    by Kathleen Iles, Mya L. Roberson, Philip Spanheimer, Kristalyn Gallagher, David W. Ollila, Paula D. Strassle, Stephanie Downs-Canner

    Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across age and nodal status. Women with HR+/HER2–, early-stage (T1-2, N0-1) breast cancers from 2010–2017 in the National Cancer Database were included. 530,125 met inclusion and 255,971 received ODX testing. Older women were less likely to receive testing; however, nodal positivity increased use of testing. High ODX RS was associated with increased mortality, though the association was not consistent across age and was most strongly associated with mortality among younger, node-negative women. Older women with high ODX RS, regardless of nodal status, were less likely to receive AC. Clinicians may be employing ODX RS to support treatment decisions against the receipt of AC.


  • Sexual harassment and women in surgery: Changing the lived experience

    by Kristalyn K. Gallagher, Apoorve Nayyar


  • Open Access

    FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

    by Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, J. Felix Olivares-Quintero, Michael P. East, Maki Tanioka, Jon S. Zawistowski, Darshan Singh, et al.

    Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site inhibitors like lapatinib, commonly lack durability because of adaptive changes in the tumor leading to resistance. HER2+ cell line responses to inhibition with lapatinib were analyzed by RNAseq and ChIPseq to characterize transcriptional and epigenetic changes. Motif analysis of lapatinib-responsive genomic regions implicated the pioneer transcription factor FOXA1 as a mediator of adaptive responses. Lapatinib in combination with FOXA1 depletion led to dysregulation of enhancers, impaired adaptive upregulation of HER3, and decreased proliferation. HER2-directed therapy using clinically relevant drugs (trastuzumab with or without lapatinib or pertuzumab) in a 7-day clinical trial designed to examine early pharmacodynamic response to antibody-based anti-HER2 therapy showed reduced FOXA1 expression was coincident with decreased HER2 and HER3 levels, decreased proliferation gene signatures, and increased immune gene signatures. This highlights the importance of the immune response to anti-HER2 antibodies and suggests that inhibiting FOXA1-mediated adaptive responses in combination with HER2 targeting is a potential therapeutic strategy.


  • Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women

    by Apoorve Nayyar, Paula D. Strassle, Kathleen Iles, Danielle Jameison, Jihane Jadi, Kandace P. McGuire, Kristalyn K. Gallagher

    Elderly women (≥ 70 years old) form a significant proportion of patients affected by breast cancer (BC); however, the treatment decisions


  • Surgical Approach to Lymphedema Reduction

    by Kristalyn K. Gallagher, Marcos Lopez, Kathleen Iles, Meredith Kugar

    Purpose of Review For patients who have or may develop lymphedema due to oncologic resection, surgical options are available to prevent and treat this chronic disease. Here, we review the current pathophysiology, classification systems, surgical preventive techniques, and treatment options for lymphedema reduction. Recent Findings Preventive surgical techniques, including de-escalation of axillary surgery, sentinel lymph node biopsy (SLNB), axillary reverse mapping (ARM), and lymphedema microsurgical preventive healing approach (LYMPHA), have been shown to reduce the incidence of lymphedema. Water displacement remains the gold standard for measuring limb volume and classification of lymphedema; however, lymphoscintigraphy and ICG lymphography are two novel imaging techniques that are now utilized to characterize lymphedema and guide management. Complete decongestive therapy (CDT) remains the mainstay of treatment. Vascularized lymph node transfer (VLNT) and lymphovenous bypass have shown promising results, particularly in advanced lymphedema stages. Combination therapy, incorporating both surgical and non-surgical approaches to lymphedema, yields best patient outcomes. Summary Lymphedema is a chronic disease wherein management requires a combination of surgical and conservative treatments. Standardization in lymphedema staging, key outcome indicators, and quantitative data will be critical to establish the absolute best practices in lymphedema diagnosis and treatment.